



Formulary Change Notice

MEDICARE ADVANTAGE | 2022

EFFECTIVE: 09/01/2022 • LAST UPDATED 08/23/2022



Effective Date	Drug Name	Change Description	Reason Description	Alternate Drug and Tier
1/1/2022	AFINITOR DISPERZ 2 MG ORAL TAB SUSP	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 2 MG ORAL TAB SUSP-5
1/1/2022	AFINITOR 10 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 10 MG ORAL TABLET-5
1/1/2022	AFINITOR DISPERZ 5 MG ORAL TAB SUSP	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 5 MG ORAL TAB SUSP-5
1/1/2022	PAXIL 10 MG/5 ML ORAL ORAL SUSP	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PAROXETINE HCL 10 MG/5 ML ORAL ORAL SUSP-2
1/1/2022	BYSTOLIC 2.5 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 2.5 MG ORAL TABLET-2
1/1/2022	AFINITOR DISPERZ 3 MG ORAL TAB SUSP	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 3 MG ORAL TAB SUSP-5
1/1/2022	CHANTIX 0.5 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VARENICLINE TARTRATE 0.5 MG ORAL TABLET-2
1/1/2022	BYSTOLIC 10 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 10 MG ORAL TABLET-2
1/1/2022	BYSTOLIC 5 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 5 MG ORAL TABLET-2

1/1/2022	BYSTOLIC 20 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	NEBIVOLOL HCL 20 MG ORAL TABLET-2
1/1/2022	DUREZOL 0.05 % OPHTHALMIC DROPS	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DIFLUPREDNATE 0.05 % OPHTHALMIC DROPS-2
1/1/2022	EPANED 1 MG/ML ORAL SOLUTION	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ENALAPRIL MALEATE 1 MG/ML ORAL SOLUTION-2
1/1/2022	CHANTIX 1 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VARENICLINE TARTRATE 1 MG ORAL TABLET-2
3/1/2022	ZOSTAVAX 19400 UNIT SUBCUTANE. VIAL	REMOVAL DUE TO U.S. MARKET AVAILABILITY (NON SAFETY RELATED)	REMOVAL DUE TO U.S MARKET AVAILABILITY (NON-SAFETY RELATED)	
3/1/2022	ZORTRESS 1 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	EVEROLIMUS 1 MG ORAL TABLET-5
5/1/2022	CARBAGLU 200 MG ORAL TAB DISPER	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	CARGLUMIC ACID 200 MG ORAL TAB DISPER-5
5/1/2022	SELZENTRY 150 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	MARAVIROC 150 MG ORAL TABLET-5
5/1/2022	SELZENTRY 300 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	MARAVIROC 300 MG ORAL TABLET-5
6/1/2022	REVLIMID 5 MG ORAL CAPSULE	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LENALIDOMIDE 5 MG ORAL CAPSULE-5
6/1/2022	REVLIMID 25 MG ORAL CAPSULE	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LENALIDOMIDE 25 MG ORAL CAPSULE-5

6/1/2022	REVLIMID 15 MG ORAL CAPSULE	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LENALIDOMIDE 15 MG ORAL CAPSULE-5
6/1/2022	REVLIMID 10 MG ORAL CAPSULE	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LENALIDOMIDE 10 MG ORAL CAPSULE-5
6/1/2022	CYSTADANE 1G/SCOOP ORAL POWDER	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	BETAINE ANHYDROUS 1G/SCOOP ORAL POWDER-5
6/1/2022	APOKYN 10 MG/ML SUBCUTANE. CARTRIDGE	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	APOMORPHINE HCL 10 MG/ML SUBCUTANE. CARTRIDGE-5
6/1/2022	VIMPAT 50 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LACOSAMIDE 50 MG ORAL TABLET-2
6/1/2022	VIMPAT 200 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LACOSAMIDE 200 MG ORAL TABLET-2
6/1/2022	VIMPAT 150 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LACOSAMIDE 150 MG ORAL TABLET-2
6/1/2022	VIMPAT 100 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LACOSAMIDE 100 MG ORAL TABLET-2
7/1/2022	CHANTIX 0.5 (11)-1 ORAL TAB DS PK	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VARENICLINE 0.5 (11)-1 ORAL TAB DS PK-2
8/1/2022	UKONIQ 200 MG ORAL TABLET	REMOVAL DUE TO FDA MARKET WITHDRAWAL		
8/1/2022	VIMPAT 10 MG/ML ORAL SOLUTION	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LACOSAMIDE 10 MG/ML ORAL SOLUTION-2

8/1/2022	BIDIL 20-37.5MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ISOSORBIDE DINIT-HYDRALAZINE 20-37.5MG ORAL TABLET-2
8/1/2022	ESBRIET 801 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PIRFENIDONE 801 MG ORAL TABLET-5
8/1/2022	ESBRIET 267 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PIRFENIDONE 267 MG ORAL TABLET-5
8/1/2022	PENNSAID 20MG/G(2%) TOPICAL SOL MD PMP	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DICLOFENAC SODIUM 20MG/G(2%) TOPICAL SOL MD PMP-5
9/1/2022	PENNSAID 20MG/G(2%) TOPICAL SOL MD PMP	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DICLOFENAC SODIUM 20MG/G(2%) TOPICAL SOL MD PMP-5
9/1/2022	VIMPAT 10 MG/ML ORAL SOLUTION	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	LACOSAMIDE 10 MG/ML ORAL SOLUTION-2
9/1/2022	TARGRETIN 1 % TOPICAL GEL (GRAM)	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	BEXAROTENE 1 % TOPICAL GEL (GRAM)-5
9/1/2022	NEXAVAR 200 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	SORAFENIB 200 MG ORAL TABLET-5
9/1/2022	ESBRIET 267 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PIRFENIDONE 267 MG ORAL TABLET-5
9/1/2022	ESBRIET 801 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PIRFENIDONE 801 MG ORAL TABLET-5
9/1/2022	TOVIAZ 4 MG ORAL TAB ER 24H	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	FESOTERODINE FUMARATE ER 4 MG ORAL TAB ER 24H-2

9/1/2022	TOVIAZ 8 MG ORAL TAB ER 24H	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	FESOTERODINE FUMARATE ER 8 MG ORAL TAB ER 24H-2
9/1/2022	VIIBRYD 40 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VILAZODONE HCL 40 MG ORAL TABLET-2
9/1/2022	VIIBRYD 20 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VILAZODONE HCL 20 MG ORAL TABLET-2
9/1/2022	VIIBRYD 10 MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	VILAZODONE HCL 10 MG ORAL TABLET-2
9/1/2022	BIDIL 20-37.5MG ORAL TABLET	BRAND VERSION REMOVED FROM FORMULARY	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ISOSORBIDE DINIT-HYDRALAZINE 20-37.5MG ORAL TABLET-2